Tue, Mar 3, 2015, 10:53 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • mega.picky mega.picky Nov 18, 2013 1:12 PM Flag

    FOLD (Mcap $ 100 M) Cash $61 M/ Blockbuster P3 results this Q / Partner GSK holds 20% of Shares !

    This is your opportunity to minimum double or triple your money on upcoming Mega Phase 3 Results which coming any day now (4Q13) .
    This undiscovered Stock trading at $2.09 which is very close to all time low but what you should know is that Pharma Giant Glaxo (GSK) bought their 10 Million shares over $6++ and Management bought over $5++ and they never sold NONE OF THIS .

    Migalastat for the treatment of Fabry disease a rare disease is in Phase 3 which is Partnered with GSK . If the Phase 3 is positive then it has Blockbuster Potential and the Low Float Stock will run like ACAD or RMTI .

    Top‐Line 12‐Month Data from Phase 3 Fabry Monotherapy Study 011 in 4Q

    My Target is $15-20 quickly after Positive Phase 3 data .GLTA

    Amicus Therapeutics (FOLD)

    Market Cap : $103 M
    Cash $61 M
    Price : $2.09

    Shares Out 49.6 M ( Institutions & Managament holding 46 M Shares)

    Glaxo hiked its stake in Amicus to 19.9%. Glaxo made an investment of $18.6 million and bought 2,949,581 shares of Amicus at $6.30 per share. We note that as of March 31, 2012, Glaxo's holding in Amicus was 14.8%, representing an equity investment of $31 million. We believe that Glaxo's increased holding in Amicus reflects its confidence in Amicus' pipeline.

    Fabry is a rare inherited disease that affects between 5,000 and 10,000 people worldwide. It’s caused by the deficiency of a specific enzyme that breaks down a fat known as globotriaosylceramide (GL-3). Without the enzyme, GL-3 builds up in blood vessels, causing a host of side effects including severe kidney damage.

    Fabry is currently treated with enzyme-replacement therapies, such as agalsidase (Fabrazyme), which are administered intravenously. Amicus’ drug is a pill. Agalsidase, sold by Sanofi/Genzyme, is the only drug approved to treat Fabry in the U.S.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.380.000(0.00%)Mar 3 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.